SAMU
ESLAW icon

SONA Asset Management (US)’s Estrella Immunopharma Warrant ESLAW Stock Holding History

SONA Asset Management (US)’s Portfolio ESLAW Stock Details ESLAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-3,540
Closed -$2K – 259
2021
Q4 		$2K Buy
+3,540
New +$1.74K ﹤0.01% 341

Other funds holding ESLAW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
EFI
EHP Funds Inc Toronto, Canada $43.6M AUM 69.08% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
WA
Whitebox Advisors Minneapolis, Minnesota $8.12B AUM 15.85% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return

SONA Asset Management (US)'s ESLAW Position: Q1 2022 in Review

SONA Asset Management (US) sold out of Estrella Immunopharma Warrant (ESLAW) in Q1 2022, closing a stake of 3,540 shares — an estimated $2K sold.

SONA Asset Management (US) first reported a position in ESLAW in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 10 funds tracked by Wall St. Rank hold ESLAW as of Q1 2022.

  • SONA Asset Management (US) reported no remaining Estrella Immunopharma Warrant position as of Q1 2022 after selling out during the quarter.
  • SONA Asset Management (US) sold 3,540 Estrella Immunopharma Warrant shares in Q1 2022, an estimated $2K.
  • SONA Asset Management (US) first reported a position in Estrella Immunopharma Warrant in Q4 2021 and held it in 1 quarter.
  • SONA Asset Management (US)'s Estrella Immunopharma Warrant position peaked at $2K in Q4 2021.
  • 10 funds tracked by Wall St. Rank held Estrella Immunopharma Warrant as of Q1 2022.

Based on SONA Asset Management (US)'s 13F filing for Q1 2022, filed 13 May 2022.